iratumumab
volociximab
besilesomab
acrixolimab
olaratumab
tislelizumab
amlitelimab
pidilizumab
sibrotuzumab
fontolizumab
zalutumumab
brolucizumab
abagovomab
inotuzumab ozogamicin
gevokizumab
etaracizumab
ravulizumab
ozogamicin
-lim-
bivatuzumab
lexatumumab
olendalizumab
intrabody
-toxa-
ipilimumab
antimonoclonal
tabalumab
dalotuzumab
agonistic monoclonal antibody
immunochemiluminometric
-zumab
tigatuzumab
rapid antigen test
brodalumab
microlymphocytotoxicity
Forssman antibody
heterophil antibody
heterophile antibody
durvalumab
immunostrip
talacotuzumab
lenzilumab
immunofluorescence
immunolabeling
antinucleosome
siltuximab
-o-
robatumumab
bectumomab
ocrelizumab